Sarepta Archives -

Young man in a wheelchair looking at the nature

Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its

Sarepta says early filing for DMD gene therapy is back on

https://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-is-back-on/

News/ News/ R&D

Myocarditis case mars Sarepta DMD gene therapy readout

Phil Taylor Duchenne muscular dystrophy, gene therapy, Pfizer, Sarepta, Solid Biosciences 0 Comment

New data on Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building

Myocarditis case mars Sarepta DMD gene therapy readout

https://pharmaphorum.com/news/myocarditis-case-mars-sarepta-dmd-gene-therapy-readout/

News/ News/ R&D

Sarepta shares yo-yo as FDA places hold on Duchenne trial

Phil Taylor Duchenne muscular dystrophy, Exondys 51, fda, rare disease, regulatory, safety, Sarepta, vesleteplirsen 0 Comment

Shares in Sarepta came under pressure after the biotech said it had temporarily halted a clinical trial of

Sarepta shares yo-yo as FDA places hold on Duchenne trial

https://pharmaphorum.com/news/sarepta-shares-yo-yo-as-fda-places-hold-on-duchenne-trial/

News/ News/ R&D

Sarepta DMD rival PepGen files $115m IPO

Phil Taylor Duchenne muscular dystrophy, financing, NS Pharma, Oligonucleotide, PepGen, Sarepta 0 Comment

Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed

Sarepta DMD rival PepGen files $115m IPO

https://pharmaphorum.com/news/sarepta-dmd-rival-pepgen-files-115m-ipo/

News/ News/ R&D

Sarepta says early filing for DMD gene therapy may be back on

Phil Taylor Duchenne muscular dystrophy, gene therapy, Pfizer, rare disease, Sarepta, Solid Biosciences 0 Comment

The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the

Sarepta says early filing for DMD gene therapy may be back on

https://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-may-be-back-on/

News/ News/ Patients

Pfizer pauses Duchenne gene therapy trial after patient death

Phil Taylor Duchenne muscular dystrophy, gene therapy, Pfizer, safety, Sarepta, Solid Biosciences 0 Comment

Pfizer has called a halt to a clinical trial of its gene therapy for Duchenne muscular dystrophy as

Pfizer pauses Duchenne gene therapy trial after patient death

https://pharmaphorum.com/news/pfizer-pauses-duchenne-gene-therapy-trial-after-patient-death/

Market Access/ News/ News

Aduhelm approval could signal new era for CNS drugs; analysts

Phil Taylor Acadia Pharmaceuticals, Aduhelm, Biogen, central nervous system, fda, Intercept Pharmaceuticals, Intra-Cellular Therapies, neurology, Psychiatry, Sarepta 0 Comment

The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the

Aduhelm approval could signal new era for CNS drugs; analysts

https://pharmaphorum.com/news/aduhelm-approval-could-signal-new-era-for-cns-drugs-analysts/

News/ News/ R&D

First UK patient joins Pfizer’s phase 3 DMD gene therapy trial

Richard Staines Duchenne muscular dystrophy, gene therapy, Pfizer, Sarepta 0 Comment

The first UK patient has enrolled on Pfizer’s phase 3 trial for its Duchenne muscular dystrophy (DMD) gene

First UK patient joins Pfizer’s phase 3 DMD gene therapy trial

https://pharmaphorum.com/news/first-uk-patient-joins-pfizers-phase-3-dmd-gene-therapy-trial/

Events/ Events

Gene Therapy for Muscular Disorders

Ellie Saunders Duchenne, gene therapy, Muscular disorders, muscular dystrophy, Sarepta 0 Comment

The ONLY digital meeting in this space!

Gene Therapy for Muscular Disorders

https://pharmaphorum.com/events/gene-therapy-for-muscular-disorders/

Trending

Sarepta

Login